A Phase 2a of RSLV-132 in Subjects With Systemic Lupus Erythematosus (SLE)

Inclusion criteria

• CLASI score greater than or equal to 10 at Baseline
• Positive for one or more RNA autoantibodies

Exclusion criteria

• severe, active central nervous system (CNS) involvement at Screening;
• severe renal involvement at Screening (urine protein/creatinine ratio of >200 mg/mmol, or an estimated creatinine clearance of <30 mL/min);
• use of cyclophosphamide within 3 months of the Baseline visit;
• use of rituximab within 6 months of the Baseline visit;
• use of belimumab within 3 months of the Baseline visit;
• use of background medications within 1 month of Baseline in excess of: i. mycophenolate mofetil > 3 g/day; ii. azathioprine > 200 mg/day; iii. methotrexate > 25 mg/day; iv. hydroxychloroquine > 400 mg/day; v. prednisone (or equivalent) > 15 mg/day;
• use of an intravenous steroid "pulse" within 2 months of Baseline;
• use of an intramuscular steroid injection within 1 month of Baseline;
• change in SLE medications within 1 month of Baseline;
• the presence of a clinically significant infection in the judgement of the Investigator within seven days prior to the receipt of the first dose of study drug;
• positive viral load test for hepatitis B, C, or HIV at Screening;
• participation in another clinical trial with receipt of an investigational product within 3 months or 5 half- lives, of last administration (whichever is longer) from Baseline;
• positive pregnancy test at Screening or at Baseline;
• female subjects currently breast feeding at Baseline;
• inability or unwillingness to comply with protocol-specified procedures which, in the opinion of the Investigator, would make the subject unsuitable for study participation.